ALKBH5 regulates IGF1R expression to promote the Proliferation and Tumorigenicity of Endometrial Cancer.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

34 citing papers in PubMed, 1 synthesis or guideline pooled it, 79 citations in OpenAlex.

1. Emerging Roles of mFrontiers in oncology · 2022
   Pooled it
2. Emerging roles of mJournal of assisted reproduction and genetics · 2026
   Review
3. m6A modification and its clinical applications in gynaecological cancer.Apoptosis : an international journal on programmed cell death · 2026
   Review
4. Microecological modulators-new perspectives for treating sex hormone disorders.Frontiers in microbiology · 2026
   Review
5. Tamoxifen differentially modulates endometrial hyperplasia via wild-type and mutant p53 regulation of the ALKBH5-REG1A axis.Frontiers in oncology · 2026
   Article
6. ALKBH5 inhibitors for cancer therapy: molecular docking, challenges and future prospects.Frontiers in pharmacology · 2026
   Review
7. Mechanistic insights into the role of RNA demethylase ALKBH5 in malignant tumor therapy.Journal of translational medicine · 2025
   Review
8. Epigenetic regulation in female reproduction: the impact of m6A on maternal-fetal health.Cell death discovery · 2025
   Review
9. M6A Demethylase ALKBH5 in Human Diseases: From Structure to Mechanisms.Biomolecules · 2025
   Review
10. Epigenetic regulation in oogenesis and fetal development: insights into m6A modifications.Frontiers in immunology · 2025
    Review
11. The role of N(6)-methyladenosine (m6a) modification in cancer: recent advances and future directions.EXCLI journal · 2025
    Review
12. DRAIC mediates hnRNPA2B1 stability and mOncogene · 2024
    Article
13. Lactate dehydrogenase A is a diagnostic biomarker associated with immune infiltration, m6A modification and ferroptosis in endometrial cancer.Frontiers in oncology · 2024
    Article
14. RNA modifications in gynecological cancer: current status and future directions.Frontiers in medicine · 2024
    Review
15. The synergistic effect of EMT regulators and m6A modification on prognosis-related immunological signatures for ovarian cancer.Scientific reports · 2023
    Article
16. New insights for gynecological cancer therapies: from molecular mechanisms and clinical evidence to future directions.Cancer metastasis reviews · 2023
    Review
17. Comprehensive immunohistochemical analysis of N6-methyladenosine (m6A) writers, erasers, and readers in endometrial cancer.Journal of cancer research and clinical oncology · 2023
    Article
18. METTL3 facilitates immunosurveillance by inhibiting YTHDF2-mediated NLRC5 mRNA degradation in endometrial cancer.Biomarker research · 2023
    Article
19. Hypoxia-induced m6A demethylase ALKBH5 promotes ovarian cancer tumorigenicity by decreasing methylation of the lncRNA RMRP.American journal of cancer research · 2023
    Article
20. Role of the RNA-binding protein family in gynecologic cancers.American journal of cancer research · 2023
    Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

3 authors at 2 institutions in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as